The Cellular antigen delivery products

Based on our Dendritic cell adjuvant technology platform, Wittycell has identified a series of natural antigen delivery systems. We developed these compounds to optimize their efficacy on CTL responses and NKT stimulation to be able to use them as adjuvants for human vaccines.

Our Dendritic cell adjuvant technology platform identified our first two candidate families. Human in vitro testing demonstrated that they are strong CTL or NKT activators.

The identification of the first two leads from these families is planned for Q3 2007.